Investors’ hub

In 2019, the global lateral flow test market was worth $8.7bn. Now it’s estimated to be worth more than $20bn. This market is growing fast – and this is your opportunity to enter it.

Revenue Model

Transform® is essentially a SaaS offer. More precisely, we are registered as providers of Software as a Medical Device (SaMD). We partner with lateral flow providers and other organisations over the long term, allowing them to integrate data capture and management capability into their lateral flow test offer. As such, Transform® is a recurring monthly revenue generator.

Our team

We are a rapidly-growing team of commercial, development and medical experts. Our senior leadership team comes from a range of sectors and its experience spans more than 50 years of international B2B and B2C sales and marketing, 30 years of start-up experience, 20 years’ digital experience, 25 years’ pharmaceutical marketing and management expertise, 25 years at the forefront of respiratory care – and 25 years in medtech business management and growth.

Existing Partners

We currently have long-term strategic contracts with partners in the UK and North America. We have delivered iterations of the platform to partners in the UK, North America and Europe – and we have more projects in the pipeline.

We have also completed a product trial in the Welsh NHS. We have launched Transform® as a COVID-19 Test and Track platform in Canada and the USA – and we’re working with companies in the USA to integrate Transform® with public health reporting systems to allow Federal-level data collection.

Existing Investors and Funding